王健博士拥有逾30年生物医疗健康领域的创业、投资、金融及科研经验。他在诺贝尔奖得主Eric Kandel的指导下获得哥伦比亚大学神经生物学博士学位，曾荣获Howard Hughes Medical Institute（HHMI）科研奖金，并拥有斯坦福大学MBA。

王博士是创响生物的董事长和CEO。创响是一家在免疫相关新药研发领域处于领先地位的生物技术公司，在圣地亚哥、上海、杭州和武汉拥有全资子公司。该公司已融资1.4亿美元，正在打造一个拥有十余个产品的强大管线，其中最成熟的候选药物IMG-020即将针对5种适应症进入全球2或3期临床试验。

王博士曾是全球最大的专注于生物医疗的投资公司奥博资本（OrbiMed）的全球合伙人及奥博亚洲（OrbiMed Asia）创始合伙人，在奥博的12年间，他联合创建并管理了11亿美元的PE/VC基金，曾被评为中国生物医疗投资Top10。他曾孵化了冠科美博（Apollomics）和Bridge（后被收购），并曾任冠科美博及时代天使公司的董事长。

他是百华协会（BayHelix，中国生物医疗商业领导者的组织）的联合创始人及前任主席，也是香港股票交易所生物科技咨询小组成员。王博士以笔名光子著有《世界边缘的秘密》《我∙世界》等科学哲学著作。

Dr. Jonathan Wang has over 30 years of healthcare and life sciences experience, spanning entrepreneurship, investment, research, and finance. Under the supervision of Eric Kandel, a Nobel Laureate, he obtained a Ph.D. in Neurobiology from Columbia University where he was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship. He also earned an MBA from Stanford University.

Dr. Wang is the Chairman and CEO of Inmagene, a leading clinical-stage biotech company focused on immunology-related therapeutic areas.  With wholly owned subsidiaries in San Diego, Shanghai, Hangzhou and Wuhan, the company has raised approximately $140M financing and is building a strong pipeline with over 10 drug candidates. The lead drug candidate, IMG-020, is about to enter global phase 2 or 3 trials for 5 autoimmune indications.

Dr. Wang was a Partner at OrbiMed, the world’s largest healthcare-dedicated investment firm.  He co-founded OrbiMed Asia where he led the establishment and management of $1.1B PE/VE funds.  He was named one of the top 10 healthcare investors in China.  He incubated Apollomics and Bridge (acquired), and served as Chairman at Apollomics and Angelalign.

He is a HKEX Biotech Advisory Panel member and a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders.  He has authored two philosophy of science books.